Coming 2019


Workshop Menu (1)

Workshop A Workshop B

Pre-Conference Workshop Day

Tuesday April 24th 2018, 9:00 am-12:00 pm


Translation from Animal to Human Studies: A Workshop on
Strategies & Applications

(This session is separately bookable)

09:00 am -12:00 pm  Workshop Leader

This interactive workshop session will delve deep into the challenges associated with the lack of predictability and robustness of pre-clinical models. Join this session to increase your rate of success in clinical development by overcoming the translational, regulatory, and financial hurdles to safely and effectively take these first in class resolution antigen-specific immune tolerance therapies from bench to bedside.

A workshop on strategies & applications

■ In which species does a novel therapy need to be tested?

■ What are the technical research issues?

■ Which disease targets are “low hanging fruit”?

■ What are the regulatory hurdles?

■ What are the Financial hurdles?

David W. Scott, Professor of Medicine & Vice Chair for Research, USUHS

Professor David W. Scott, Ph.D. is Vice Chair for Research in the Department of Medicine at the Uniformed Services School of Health Sciences, Bethesda, MD, since 2010. An alumnus of Antioch, University of Chicago and Yale, and a post-doc at Oxford, he held tenured faculty positions at Duke, University of Rochester, and the U. Maryland Medical School. Dr. Scott has contributed to over 200 research papers on several subjects on immunologic tolerance, and its application in hemophilia. The author of two textbooks and recipient of a number of awards from the AAI, a Boerhaave Professorship at Leiden University and a Scientific Achievement Award from AAPS.


Tuesday April 24th 2018, 1:00 pm-4:00 pm


How to Induce Antigen-Specific Immune Tolerance Through Nanoparticles as a Platform?

(This session is separately bookable)

1:00 pm – 4:00 pm  Workshop Leader
Tolerogenic nanoparticles are rapidly being developed as specific immunotherapies to treat autoimmunity. However, as with any emerging approach, there are many uncertainty associated with the safety, efficacy and design and administration process of nanoparticles. This workshop highlights the challenges and opportunities of a nanoparticle approach to immune tolerance induction by addressing the fundamentals in-depth:

■ How to best define the spectrum of self antigens driving a particular autoimmune disease to be targeted for tolerance induction?

■ What preclinical models are necessary to test before firstin-man clinical trials?

■ What are the optimal disease indications for first assessing successful tolerance induction in man?

■ How to best determine the nanoparticle composition and route of administration for developing a robust tolerance therapy?

■ How to best design a clinical trial to assess the mechanisms underlying tolerance induction and maintenance in man?

Stephen Miller, Professor at Northwestern University Medical School & Co-founder, Cour Pharmaceutical Dev. Company

Dr. Stephen Miller is the Judy E. Gugenheim Research Professor of Microbiology-Immunology at Northwestern University Feinberg School of Medicine in Chicago and he currently serves as Director of the Northwestern University Interdepartmental Immunobiology Center. Dr. Miller’s work has significantly enhanced understanding of immune inflammatory processes underlying chronic autoimmune disease employing animal models of multiple sclerosis (MS) and Type 1 diabetes (T1D). His current work is geared to translating the use of antigen-linked  iodegradable PLG nanoparticles for the treatment of human immune-mediated diseases including autoimmunity, allergy and  tissue/organ transplantation.